Once-daily Rhinocort® offers
unsurpassed efficacy, proven long-term safety, essentially no taste
or added fragrance, and does not contain benzalkonium chloride or alcohol. Rhinocort® is the
first-line treatment of choice for all patients with seasonal
(intermittent) and perennial
(persistent) allergic
rhinitis, aged 6 years and over,
suffering more than very mild or intermittent nasal symptoms.
Rhinocort® also provides
highly effective once-daily relief of the symptoms of nasal polyposis.
Rhinocort®
is approved for use in the treatment of allergic rhinitis and nasal
polyps. Three different formulations of Rhinocort® are currently
available – although not all formulations and strengths are
available in all countries
-
Rhinocort®
Aqua™ aqueous nasal spray 32, 50, 64 and 100 µg
strengths (alternative trademarks include: Budecort Nasal®,
Pulmicort Nasal®, Rhinocortol® and Pulmicort Topinasal®)
-
Rhinocort®
Turbuhaler® nasal dry powder inhaler 100 µg strength
(alternative trademarks include: Spirocort® Nasal Turbuhaler®)
-
Rhinocort® pMDI pressurised metered-dose inhaler 50 µg strength
(alternative trademarks include: Rhinocort® Nasal Inhaler)
|
